Aevi Genomic Medicine (GNMX) announced Monday morning that its SAGA trial of AEVI-001 in adolescents with mGluR mutation positive ADHD did not meet the primary endpoint of reduction on the ADHD rating scale compared to placebo.
from RTT - Before the Bell http://ift.tt/2nNHxI0
via IFTTT
No comments:
Post a Comment